# A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors

Source: https://onco.cc/trials/nct06520488/  
OnCo record `nct06520488` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HRS-4642 in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06520488 by Jiangsu HengRui Medicine Co., Ltd., with 118 participants planned, started 2024-08-09 and due to reach its primary completion in 2027-03. Interventions recorded: HRS-4642.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06520488
- Phase: 1/2
- Setting: Phase IB/II Clinical Study of the Safety, Tolerability and Efficacy of HRS-4642 in Combination With Anti-tumor Agents in Subjects With Advanced Solid Tumors
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 118

## Sources

- ClinicalTrials.gov NCT06520488: https://clinicaltrials.gov/study/NCT06520488

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06520488.json